Adam Vasconcellos, MD
Otolaryngology · Wyomissing, PANPI 1386939023
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 74.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $857 and has fallen 94.9% since, to $44 in 2025.
Across 15 payments — averaging $71.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$801
- Smith+Nephew$219
- Baxter Healthcare$39
- Stryker$21
Across 16 payments — averaging $2195.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inspire Medical Systems, Inc.$35K
What the payments were for
- Travel & lodging$60556%
- Food & beverage$22521%
- Education$21120%
- Other$394%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 11 | $801 |
| Smith+Nephew | 2 | $219 |
| Baxter Healthcare | 1 | $39 |
| Stryker | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,080 in reported general payments places this provider in the 55th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 163 | $5,349 |
| Fluticasone Propionate | 206 | $3,308 |
| Ipratropium Bromide | 40 | $1,632 |
| Ofloxacin | 40 | $807 |
| Omeprazole | 57 | $522 |
| Cefdinir | 19 | $421 |
| Pantoprazole Sodium | 21 | $274 |
| Methylprednisolone | 35 | $254 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $217 |
| Famotidine | 27 | $196 |
| Levothyroxine Sodium | 17 | $168 |
| Mometasone Furoate | 17 | $162 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Wyomissing
- Nancy SnydermanPhiladelphia$4.5M
- David YenBethlehem$1.4M
- David KennedyPhiladelphia$603K
- Stella LeePittsburgh$438K
- James PalmerPhiladelphia$331K
- Ryan SooseSeven Fields$134K
- Mathew NagorskyPhiladelphia$95K
- Noam CohenPhiladelphia$76K
- Nithin AdappaPhiladelphia$72K
- Matthew SpectorPittsburgh$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.